^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golidocitinib (DZD4205)

    i
    Other names: DZD4205, AZD-4205, AZD 4205, AZD4205, DZD-4205
    Company:
    Dizal Pharma
    Drug class:
    JAK1 inhibitor
    Related drugs:
    17h
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    7d
    Golidocitinib Combined With Selinexor for CAEBVD (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    Xpovio (selinexor) • golidocitinib (DZD4205)
    13d
    Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma. (PubMed, Blood Adv)
    In alignment with our experimental findings, relapsed or refractory PTCL patients with high serum FFA exhibited superior responses to golidocitinib treatment than those with low serum FFA. Collectively, high serum FFA is related to tumor progression and indicates golidocitinib sensitivity, providing novel insights into reprogramming lipid metabolism to dually target the tumor and microenvironment in PTCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    ALK positive • ALK negative
    |
    golidocitinib (DZD4205)
    20d
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH. (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    golidocitinib (DZD4205)
    20d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    1m
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    1m
    A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) (clinicaltrials.gov)
    P2, N=90, Recruiting, Dizal Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Zegfrovy (sunvozertinib) • golidocitinib (DZD4205)
    1m
    JACKPOT22: Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New P2 trial
    |
    golidocitinib (DZD4205)
    1m
    AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) (clinicaltrials.gov)
    P2, N=57, Completed, Dizal Pharmaceuticals | Recruiting --> Completed | N=150 --> 57 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    golidocitinib (DZD4205)
    1m
    T-START-M1: Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=136, Not yet recruiting, Fudan University
    New P3 trial
    |
    golidocitinib (DZD4205)
    1m
    Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    golidocitinib (DZD4205)
    2ms
    Golidocitinib Combined With GemOx in RR PTCL (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    oxaliplatin • golidocitinib (DZD4205)